Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms
- Rongjia Zhu
- , Tingdong Yan
- , Yingmei Feng
- , Yan Liu
- , Hongcui Cao
- , Gongxin Peng
- , Yanlei Yang
- , Zhen Xu
- , Jingqi Liu
- , Wei Hou
- , Xiaoyue Wang
- , Zhe Li
- , Luchan Deng
- , Shihua Wang
- , Jing Li
- , Qin Han
- , Hongling Li
- , Guangliang Shan
- , Yinghao Cao
- , Xingyan An
- Chinese Academy of Medical Sciences
- Shanghai University
- Capital Medical University
- Wuhan University of Science and Technology
- Zhejiang University
- National Clinical Research Center for Infectious Diseases
- Versiti Blood Research Institute
- CAS - Shanghai Institute of Nutrition and Health
- Ltd.
- International Society on Aging and Disease
- Université Côte d'Azur
- CHU de Nice
- The University of Hong Kong
- RAS - Institute of Biology of the Komi Science Centre, Ural Branch
- Russian Gerontological Research Clinical Center
- University of Valencia
- Maharishi Markandeshwar University, Mullana
- Karolinska Institutet
- University of Macau
- Tsinghua University
- University of North Dakota
- Inha University
- King's College London
- University of Palermo
- University of North Texas Health Science Center
Research output: Contribution to journal › Article › peer-review
110
Scopus
citations